Search results for query: *

Just wanted to point out some information that has been analyzed: "Knopp Biosciences is very pleased to see dexpramipexole entering Phase III development with the initiation of the EMPOWER study," said Michael Bozik, M.D., President and CEO of Knopp. "The promise of dexpramipexole has brought...

ALS treat us now is asking for Biogen to give us the CHOICE to have access to dexpramipexole which *has shown safety and efficacy in the first and second phase of trials.* Of course there would be paperwork in place just like in the clinical trials for Biogens "protection." This request for...